How should bradycardia associated with acyclovir (Zovirax) be managed?

Management of Acyclovir-Associated Bradycardia

Immediately discontinue acyclovir if new-onset bradycardia develops during therapy, as this is a rare but documented adverse effect that typically resolves within 3 days of drug cessation. 1

Initial Assessment and Recognition

When bradycardia (heart rate <50 bpm) occurs in a patient receiving acyclovir, evaluate for:

• Symptom severity: Assess for hypotension, altered mental status, ischemic chest discomfort, acute heart failure, or other signs of shock 2
• Timing of onset: Acyclovir-induced bradycardia typically develops within the first few days of intravenous therapy 1
• Baseline cardiac function: Obtain 12-lead ECG to characterize the rhythm and rule out AV block 2
• Alternative causes: Exclude electrolyte abnormalities (hyperkalemia, hypokalemia), hypothyroidism, acute MI, hypothermia, and other medications that may contribute 3

Immediate Management Algorithm

For Symptomatic Bradycardia with Hemodynamic Compromise:

1. Stop acyclovir immediately 1, 4

   • Bradycardia typically resolves within 3 days of discontinuation 1
   • Consider alternative antiviral agents if continued therapy is essential

2. Administer atropine 0.5 mg IV 5, 2, 3

   • Repeat every 3-5 minutes as needed up to maximum 2.0 mg 5
   • Titrate to achieve heart rate of approximately 60 bpm 5
   • Caution: Doses <0.5 mg may paradoxically slow heart rate 5

3. If unresponsive to atropine, initiate chronotropic support 6, 3:

   • Dopamine infusion: 5-20 mcg/kg/min for chronotropic effect 3
   • Epinephrine infusion: 2-10 mcg/min, titrate to effect 3
   • Isoproterenol: May be considered if low likelihood of coronary ischemia 3

4. Transcutaneous pacing 5, 6, 2:

   • Initiate if bradycardia persists despite pharmacologic therapy 6
   • Apply pacing patches as standby measure while preparing for potential transvenous pacing 5

For Asymptomatic or Minimally Symptomatic Bradycardia:

• Discontinue acyclovir and monitor closely 1
• No acute pharmacologic intervention required if hemodynamically stable 5, 2
• Continuous cardiac monitoring until heart rate normalizes 2
• Expect resolution within 72 hours of drug cessation 1

Mechanism and Clinical Context

Acyclovir-induced bradycardia appears to involve reversible autonomic neuropathy with marked reduction in serum catecholamines 4. This is an extremely rare adverse effect with only three documented cases in the literature 1. The bradycardia can be profound (as low as 35 bpm) and may be accompanied by hypotension 1, 4.

Key Clinical Pitfalls

• Do not continue acyclovir once bradycardia is identified, as the effect is dose-dependent and reversible 1, 4
• Avoid atropine in heart transplant patients without autonomic reinnervation, as it will be ineffective 3
• Do not use routine pacing unless symptomatic or hemodynamically unstable 5, 2
• Monitor renal function: Acyclovir dosing should already be adjusted for renal impairment, but bradycardia may occur regardless 7

Alternative Antiviral Considerations

If continued antiviral therapy is essential after acyclovir discontinuation:

• For HSV/VZV encephalitis: Continue monitoring as acyclovir remains first-line, but consider risk-benefit if bradycardia recurs 7, 8
• For less severe HSV infections: May consider oral alternatives once hemodynamically stable 9
• Consult infectious disease for guidance on alternative agents in severe cases requiring continued IV therapy 7

Monitoring After Resolution

• Continuous cardiac monitoring until heart rate stable >50 bpm for 24 hours 2
• Serial ECGs to document resolution and exclude conduction abnormalities 2
• Avoid rechallenge with acyclovir if alternative agents are available 1